Cover Image
市場調查報告書

超氧化物歧化酶 (Cu-Zn) :開發中產品分析

Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364836
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
超氧化物歧化酶 (Cu-Zn) :開發中產品分析 Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 58 Pages
簡介

本報告提供以超氧化物歧化酶 (Cu-Zn) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

超氧化物歧化酶 (Cu-Zn)的概要

治療藥的開發

超氧化物歧化酶 (Cu-Zn) :開發中的產品 - 各開發階段

超氧化物歧化酶 (Cu-Zn) :開發中的產品 - 各治療範圍

超氧化物歧化酶 (Cu-Zn) :開發中的產品 - 各適應症

超氧化物歧化酶 (Cu-Zn) :開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

超氧化物歧化酶 (Cu-Zn) :企業開發中的產品

超氧化物歧化酶 (Cu-Zn) :大學/機關開發中的產品

超氧化物歧化酶 (Cu-Zn) :治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

超氧化物歧化酶 (Cu-Zn)的治療藥開發企業

  • Ionis Pharmaceuticals, Inc.
  • Neurimmune Holding AG
  • ProMIS Neurosciences Inc.
  • RXi Pharmaceuticals Corporation
  • Voyager Therapeutics, Inc.

藥物簡介

超氧化物歧化酶 (Cu-Zn) :暫停中的計劃

超氧化物歧化酶 (Cu-Zn) :主要消息和新聞稿

附錄

目錄
Product Code: GMDHC0099TDB

Summary

Global Markets Direct's, 'Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Pipeline Review, H1 2016', provides in depth analysis on Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1)
  • The report reviews Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) Overview
  • Therapeutics Development
    • Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Products under Development by Stage of Development
    • Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Products under Development by Therapy Area
    • Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Products under Development by Indication
  • Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Products under Development by Companies
  • Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Products under Development by Universities/Institutes
  • Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Companies Involved in Therapeutics Development
    • Ionis Pharmaceuticals, Inc.
    • Neurimmune Holding AG
    • ProMIS Neurosciences Inc.
    • RXi Pharmaceuticals Corporation
    • Voyager Therapeutics, Inc.
  • Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Drug Profiles
    • ISIS-SOD1Rx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit SOD1 for Amyotropic Lateral Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NI-204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RNAi Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RNAi Oligonucleotide to Inhibit SOD-1 for ALS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate SOD-1 for Amyotrophic Lateral Sclerosis and Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TDI-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetrathiomolybdate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VYSOD-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WTX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Dormant Projects
  • Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Featured News & Press Releases
    • May 30, 2016: Wilson Therapeutics Presents Encouraging Clinical Data On Decuprate At The Congress Of The European Academy Of Neurology
    • May 18, 2016: Wilson Therapeutics Announces That the Ongoing Phase II Study Has Been Fully Enrolled
    • Apr 29, 2016: Voyager Therapeutics Highlights Program in ALS Disease
    • Apr 14, 2016: Wilson Therapeutics presents data on Decuprate™ (WTX101) from ongoing Phase 2 study at The International Liver Congress™ 2016
    • Dec 11, 2015: Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS
    • Apr 16, 2015: Wilson Therapeutics Announces Presentation Of WTX101-201 Phase 2 Study At The EASL 50th International Liver Congress 2015
    • Nov 17, 2014: Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients
    • Jan 13, 2014: Wilson Therapeutics Announces Successful Filing of U.S. IND to Advance WTX101 Development Program for Wilson Disease
    • Apr 03, 2013: MGH And Washington University Researchers Announce Isis Pharma's SOD1 Antisense Drug Demonstrates Safety In Phase I ALS Trial
    • Feb 13, 2013: Copper Depletion Therapy May Prevent Risk Of Triple-Negative Breast Cancer, Study Finds
    • Apr 28, 2011: RXi Pharmaceuticals and the University of Massachusetts Medical School Announce Massachusetts Life Sciences Center Cooperative Research Grant for RNAi Therapeutics for ALS
    • Mar 08, 2010: ISIS Initiates Phase I Clinical Trial Of ISIS-SOD1Rx In Patients With Amyotrophic Lateral Sclerosis
    • Dec 13, 2007: Isis Pharmaceuticals Announces ISIS 333611 Granted Orphan Drug Status For Treatment Of ALS
    • May 24, 2004: Attenuon Announces Launch Of ATN-224 Phase I Trial In Patients With Solid Tumors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
  • Pipeline by Neurimmune Holding AG, H1 2016
  • Pipeline by ProMIS Neurosciences Inc., H1 2016
  • Pipeline by RXi Pharmaceuticals Corporation, H1 2016
  • Pipeline by Voyager Therapeutics, Inc., H1 2016
  • Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top